  | Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015  Peer Reviewed verified by ORBi |
 | Zegels, B., LEONORI, L., Crozes, P., Uebelhart, D., Bruyère, O., & Reginster, J.-Y. (April 2013). Equivalence of a single dose (1200mg) compared to a 3-time a day dose (400mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis: Results of a randomized double blind placebo controlled study. Osteoporosis International, 24 (Suppl.1), 383. Peer Reviewed verified by ORBi |
 | Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (April 2013). Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture. Rheumatology International, 33 (4), 979-83. doi:10.1007/s00296-012-2461-x Peer Reviewed verified by ORBi |
 | Zegels, B., Crozes, P., Uebelhart, D., Bruyère, O., & REGINSTER, J.-Y. (2013). Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis and Cartilage, 21 (1), 22-27. doi:10.1016/j.joca.2012.09.017 Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2013). Evaluation de l'amélioration cliniquement pertinente ressentie par les patients sous différents modes d'administration de sulfate de chondroïtine : résultats d'une étude randomisée, contrôlée et en double insu. Revue du Rhumatisme, 80 (S1), 123-A124. Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., HUSKIN, J.-P., & Reginster, J.-Y. (2012). Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery. doi:10.1007/s00402-012-1583-7 Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., ZEGELS, B., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., LEONORI, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (March 2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Osteoporosis International, 23 (Suppl. 2), 362-363. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Osteoporosis International, 23 (Suppl. 2), 363-364. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., Leonori, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 20, 124-130. doi:10.1016/j.ctim.2011.12.007 Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333. Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334. Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68. Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (November 2010). Etude de la qualité de vie après la mise en place d’une prothèse de hanche ou de genou pour cause d’arthrose : une étude de cohorte avec un suivi de 7 ans. Revue du Rhumatisme, 77 (Suppl.3), 141. Peer Reviewed verified by ORBi |
  | Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469. Peer Reviewed verified by ORBi |
 | Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (May 2010). Health-related quality of life after total knee or hip replacement : a 7-year prospective study. Osteoporosis International, 21 (Suppl.1), 26. Peer Reviewed verified by ORBi |
 | Zegels, B., Theiler, M., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (May 2010). Single oral dose of (1200 mg) sachet of chondroitin 4&6 sulfate (CS) relieves pain and improves function. Results of a double-blind study, versus placebo and an active treatment in knee OA patients. Osteoporosis International, 21 (Suppl.1), 356. Peer Reviewed verified by ORBi |
 | ZEGELS, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2009). Une prise orale unique (1200 mg) de sulfate de chondroïtine 4 & 6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrants de gonarthrose (OA). Revue du Rhumatisme, 76, 1071. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1 Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (April 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Osteoporosis International, 19 (Suppl.1), 200. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Heraud, F., Zegels, B., & Bruyère, O. (October 2007). Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Reviews in Medicinal Chemistry, 7 (10), 1051-1061. doi:10.2174/138955707782110088 Peer Reviewed verified by ORBi |
 | Gadois, C., Zegels, B., Dohuu, J. P., Lespessailles, E., Neveu, J. P., Fardellone, P., Roux, C., Kolta, S., & Reginster, J.-Y. (March 2007). Effect of age on a fractal bone texture parameter assessed by high resolution digital X Ray: a multicenter pilot study. Osteoporosis International, 18 (Suppl.1), 102. Peer Reviewed verified by ORBi |
Zegels, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2007). Une prise orale unique (1200mg) de sulfate de chondroitine 4&6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrant de gonarthrose (OA). In Revue du Rhumatisme. Peer reviewed |
 | Manette, C., Collette, J., Sarlet, N., Tancredi, A., Zegels, B., & Reginster, J.-Y. (2006). Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate. Current Medicinal Chemistry, 13 (13), 1585-1590. doi:10.2174/092986706777442057 Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Christgau, S., Cloos, P., Bang Henriksen, D., Chapelle, J.-P., Zegels, B., Reginster, J.-Y., & Henrotin, Y. (March 2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 13 (3), 258-265. doi:10.1016/j.joca.2004.12.002 Peer Reviewed verified by ORBi |
 | Hanssens, L., Tancredi, A., DeCeulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (May 2004). Evaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 15 (Suppl.1), 48-49. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarkar, S., Zegels, B., Henrotin, Y., Bruyère, O., Agnusdei, D., & Collette, J. (February 2004). Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. BONE, 34 (2), 344-351. doi:10.1016/j.bone.2003.10.004 Peer Reviewed verified by ORBi |
 | Hanssens, L., Tancredi, A., De Ceulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (November 2003). Evaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 14 (Suppl. 7), 90-S91. Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Christgau, S., Henriksen, D. B., Zegels, B., & Reginster, J.-Y. (November 2003). Cartilage degradation and oxidative damage in OA and RA patients. Osteoporosis International, 14 (Suppl. 7), 44-45. Peer Reviewed verified by ORBi |
Ethgen, O., Tancredi, A., Lejeune, E., Kvasz, A., Zegels, B., & Reginster, J.-Y. (November 2003). Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index. Journal of Rheumatology, 30 (11), 2452-2459. Peer Reviewed verified by ORBi |
 | Bruyère, O., Dardenne, C.-B., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Ethgen, O., Henrotin, Y., & Reginster, J.-Y. (May 2003). Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. BONE, 32 (5), 541-545. doi:10.1016/S8756-3282(03)00059-0 Peer Reviewed verified by ORBi |
 | Bruyère, O., Lambert, V., Dardenne, C., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (November 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Osteoporosis International, 13 (Suppl.3), 51-52. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvasz, A., & Reginster, J.-Y. (November 2002). A comparative analysis between the time trade-off and the willingness to pay approaches in hip and knee osteoarthritis. Osteoporosis International, 13 (Suppl. 3), 47. Peer Reviewed verified by ORBi |
 | Bruyère, O., LAMBERT, V., Dardenne, C., Lejeune, E., Zegels, B., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (September 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Arthritis and Rheumatism, 16 (number 9 (suppl.)), 154. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvazs, A., & Reginster, J.-Y. (September 2002). Do willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis? Arthritis and Rheumatism, 46 (number 9 (suppl.)), 73. Peer Reviewed verified by ORBi |
 | Sedrine, W. B., Chevallier, T., Zegels, B., Kvasz, A., Micheletti, M. C., Gelas, B., & Reginster, J.-Y. (June 2002). Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecological Endocrinology, 16 (3), 245-250. doi:10.1080/gye.16.3.245.250 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Kvsaz, A., Seidel, L., & Sarlet, N. (February 2002). Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion. Calcified Tissue International, 70 (2), 78-82. doi:10.1007/s00223-001-0034-1 Peer Reviewed verified by ORBi |
 | Goemaere, S., Zmierczak, H., Van Pottelbergh, I., Toye, K., Daems, M., Zegels, B., Reginster, J.-Y., & Kaufman, J. M. (2002). Prediction of bone mineral density by estrogens precursors, estradiol, SHBG and BMI in elderly women at risk for osteoporotic fractures. Osteoporosis International, 13 (S1), 102. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J. P., Kaufman, J. M., Goemaere, S., Depresseux, G., Zegels, B., Deroisy, R., & Reginster, J.-Y. (October 2001). Evaluation of the Simple Calculated Osteoporosis Risk Estimation (Score) in a Sample of White Women from Belgium. BONE, 29 (4), 374-80. doi:10.1016/S8756-3282(01)00583-X Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Taquet, A. N., & Albert, A. (February 2001). Influence of Daily Calcium and Vitamin D Supplementation on Parathyroid Hormone Secretion. Gynecological Endocrinology, 15 (1), 56-62. doi:10.1080/gye.15.1.56.62 Peer Reviewed verified by ORBi |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Clinical Rheumatology, 5 (Suppl.1), 411. Peer Reviewed verified by ORBi |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Osteoarthritis and Cartilage, 9 (Suppl.B), 61. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., DEROISY, R., Lejeune, E., & Taquet, A. (2001). The timing, dose and choice of calcium and vitamin D. BONE, S28, 253. Peer Reviewed verified by ORBi |
 | Zegels, B., Eastell, R., Russell, R. G., Ethgen, D., Roumagnac, I., Collette, J., & Reginster, J.-Y. (January 2001). Effect of High Doses of Oral Risedronate (20 Mg/Day) on Serum Parathyroid Hormone Levels and Urinary Collagen Cross-Link Excretion in Postmenopausal Women with Spinal Osteoporosis. BONE, 28 (1), 108-12. doi:10.1016/S8756-3282(00)00410-5 Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Zegels, B., DEROISY, R., & Reginster, J.-Y. (2001). Evaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium. Clinical Rheumatology, 20, 420. Peer Reviewed verified by ORBi |
 | Zmierczak, H., Goemaere, S., Daems, M., Toye, K., Zegels, B., Reginster, J.-Y., & Kaufman, J. (2001). Relationship between estrogen precursors, estradiol, body mass index and bone mineral dentiy in elderly women at risk of osteoporotic fractures. Clinical Rheumatology, 20, 422. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. BONE, S28, 244. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of a daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. Clinical Rheumatology, 20, 424. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sakar, S., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., Wrong, M., Harper, K., & Agnusdei, D. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. BONE, 28 (Suppl.1), 239. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., & Durez, P. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. Clinical Rheumatology, 5 (Suppl.1), 425. Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., Zegels, B., Rovati, L. C., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (2000). Baseline values and early (6-month) changes in total and bone specific alkaline phosphatase do not predict long-term (4-year) bone mineral density changes in postmenopausal osteoporotic women treated with fluoride. Arthritis and Rheumatism, 43 (S1), 199. Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., CREMERS, S., Demuynck, R., Daems, M., Dobbelaere, K., Ben Sedrine, W., Albert, A., Dewé, W., Kaufman, J., & Reginster, J.-Y. (1999). Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors. Calcified Tissue International, 65 (5), 354-358. doi:10.1007/s002239900712 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L. C., Minne, H. W., Giacovelli, G., Taquet, A. N., Setnikar, I., Collette, J., & Gosset, C. (01 July 1998). The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial. Annals of Internal Medicine, 129 (1), 1-8. doi:10.7326/0003-4819-129-1-199807010-00001 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Collette, J., Albert, A., & Zegels, B. (March 1997). Prediction of Bone Loss Rate in Healthy Postmenopausal Women. Calcified Tissue International, 60 (3), 261-4. doi:10.1007/s002239900226 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Zegels, B., Denis, D., Reginster-Haneuse, G., Wilkin, P., Taziaux, P., Albert, A., & Boelen, C. (1997). Prévention de l'ostéoporose à Liège. Evaluation d'un essai de partenariat entre médecins généralistes et spécialistes universitaires (1). Revue Médicale de Liège, 52 (1), 31-36. Peer reviewed |
Reginster, J.-Y., Taquet, A. N., Fraikin, G., Gosset, C., & Zegels, B. (1997). Parathyroid hormone in the treatment of involutional osteoporosis : back to the future. Osteoporosis International, 7 (Suppl 3), 163-8. doi:10.1007/BF03194365 Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Calcified Tissue International, 61, 502. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L., Minne, H., Giacovelli, G., Taquet, A., Setnikar, I., & Collette, J. (1997). Sodium monofluorophosphate reduces vertebral fractures in moderate postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 104. Peer Reviewed verified by ORBi |
 | Clemmesen, B., Ravn, P., Zegels, B., Taquet, A., Christiansen, C., & Reginster, J.-Y. (1997). A 2-year phase II study with 1-year of follow-up of risedronate (NE58095) in postmenopausal osteoporosis. Osteoporosis International, 7, 488-495. doi:10.1007/PL00004152 Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnosis efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 495. Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., FREDERICK, I., Zegels, B., Taquet, A., Noel, V., Albert, A., & Reginster, J.-Y. (1996). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Archives of Public Health, 53 (S1), 37. Peer Reviewed verified by ORBi |
 | Taquet, A., Clemmensen, B., Zegels, B., Ravin, P., Christiansen, C., Roumagnac, I., & Reginster, J.-Y. (1996). A three-year double-blind placebo-controlled study of risedronate in postmenopausal osteoporosis. Osteoporosis International, 6 (S1), 262. Peer Reviewed verified by ORBi |
 | Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Réduction de l’incidence fracturaire vertébrale chez des femmes ostéoporotiques traitées par monofluorophosphate de sodium : une étude randomisée, placebo-controllée et double aveugle. Revue du Rhumatisme, 63, 788. Peer Reviewed verified by ORBi |
 | Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Sodium monofluorophosphate reduces fracture incidence in women with postmenopausal osteoporosis : a randomized, placebo-controlled, double-blind study. Revue du Rhumatisme, 63, 672. Peer Reviewed verified by ORBi |
 | Zegels, B., Taquet, A., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1996). Biochemical evidence of antiresorptive effect of risedronate in established osteoporosis. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Denis, D., SARLET, N., Reginster-Haneuse, G., Albert, A., & Boelen, C. (1996). Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 2, 139-150. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Meurmans, L., Rovati, L., Taquet, A., Setnikar, I., & COLLETTE, J. (1996). Monofluorophosphate decreases vertebral fracture rate in postmenopausal osteoporosis: a randomised, placebo-controlled, double blind study. Osteoporosis International, 6 (S1), 239. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Longueville, M., & Franchimont, P. (May 1995). A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss. American Journal of Medicine, 98 (5), 452-8. doi:10.1016/S0002-9343(99)80344-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Zegels, B., Jupsin, I., Albert, A., & Franchimont, P. (March 1995). Long-Term Performance in Vitro and in Vivo of Dual-Energy X-Ray Absorptiometry. Clinical Rheumatology, 14 (2), 180-6. doi:10.1007/BF02214940 Peer Reviewed verified by ORBi |
Zegels, B., Balena, R., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1995). Effect of risedronate on collagen cross-links in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 10 (s1), 455. Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Revue du Rhumatisme, 10, 763. Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Archives of Public Health, 52 (S1), 81. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Janssen, C., DEROISY, R., Zegels, B., Albert, A., & FRANCHIMONT, P. (1995). Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clinical Rheumatology, 14 (1), 68-75. doi:10.1007/BF02208087 Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Journal of Bone and Mineral Research, 10 (S1), 463. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Denis, D., Deroisy, R., Lecart, M. P., De Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (January 1994). Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin. Journal of Bone and Mineral Research, 9 (1), 69-73. doi:10.1002/jbmr.5650090110 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., Zegels, B., & Franchimont, P. (1994). Acute biochemical variations induced by four different calcium salts in healthy male volunteers. Equilibre, 19, 5. Peer reviewed |
 | Reginster, J.-Y., Denis, D., Bartsch, V., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Acute Biochemical Variations Induced by Four Different Calcium Salts in Healthy Male Volunteers. Osteoporosis International, 3, 271-5. doi:10.1007/BF01623832 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Gaspar, S., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Prevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation. Osteoporosis International, 3, 261-4. doi:10.1007/BF01623830 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Darte, C., COLLETTE, J., DEROISY, R., & Franchimont, P. (1993). New radioimmunoassay for determination of bone specific iso-enzymes of serum alkaline phosphatases activity (Ostase°): validation and clinical perspective. Journal of Bone and Mineral Research, 8 (S1), 261. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ethgen, D., Barbier, A., Geusens, P., Lecart, M., Chappard, D., de Vernejoul, M., Zegels, B., & Franchimont, P. (1993). Evidence that tiludronate is an interesting perspective for prevention and treatment of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 8 (S1), 326. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Meurmans, L., Bekkering, M., Rovati, L., Setnikar, I., & Franchimont, P. (1993). Efficacy and safety of monofluorophosphate and calcium in postmenopausal osteoporosis. Revista Espanola de Reumatologia: Organo Oficial de la Sociedad Espanola de Reumatologia, 20 (S1), 186. Peer reviewed |
 | Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Sarlet, N., de Longueville, M., Albert, A., & Franchimont, P. (1993). Nasal salmon calcitonin for prevention of early postmenopausal bone loss: a dose-ranging placebo controlled study. Journal of Bone and Mineral Research, 8 (S1), 340. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Zegels, B., Lecart, M., Denis, D., & Franchimont, P. (1992). Intérêts et limites de l'absorptiométrie biphotonique dans le dépistage de l'ostéoporose postménopausique. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 511. Peer Reviewed verified by ORBi |